Phathom Pharmaceuticals, Inc. (PHAT)
PHAT moved a median of -0.26% 30 minutes after news, and -0.85% by the close. How PHAT actually reacts to news — the realized, point-in-time move the market made, measured across 292 labeled events over the last three years with zero look-ahead.
PHAT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 47% | 291 |
| 30-min | -0.26% | 45% | 292 |
| 60-min | -0.32% | 43% | 292 |
| to close | -0.85% | 40% | 290 |
| Middle 50% of PHAT reactions | -2.04% to +1.38% |
|---|---|
| Median reaction (30-min) | -0.26% |
| Measured reactions | 292 |
Half of all Phathom Pharmaceuticals, Inc. news events land between -2.04% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PHAT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 12 | -0.17% | 50% | -3.83% |
| Rating reiterations | 118 | +0.04% | 51% | -0.96% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PHAT ranks against every other measured name →
That’s how PHAT usually reacts — get an email when it moves on news →Email me when PHAT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PHAT's baseline. Nothing else.
Recent PHAT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 | Press release | GlobeNewswire | -0.69% | -1.66% | |
| Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting | Press release | GlobeNewswire | -1.32% | +5.01% | |
| Form 8-K Phathom Pharmaceuticals, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | -1.35% | |
| Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD | Press release | GlobeNewswire | +0.58% | +0.27% | |
| PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.77% | -0.77% | |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.84% | -1.68% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.11% | +1.77% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.23% | +7.76% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -1.73% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.18% | — | |
| Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.06% | +1.91% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.06% | -3.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.35% | -0.47% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.29% | +2.63% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.72% | -3.26% | |
| Form 10-Q Phathom Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +13.08% | +1.46% | |
| Form 8-K Phathom Pharmaceuticals, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +13.08% | +1.46% | |
| Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +13.08% | +1.46% | |
| Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 | Press release | GlobeNewswire | +2.05% | -2.29% | |
| Form 8-K Phathom Pharmaceuticals, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | -0.37% | |
| Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) | Press release | GlobeNewswire | +0.87% | -0.37% | |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.93% | -2.66% | |
| Form 8-K Phathom Pharmaceuticals, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -2.66% | |
| Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting | Press release | GlobeNewswire | +0.90% | +1.89% | |
| Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting | Press release | GlobeNewswire | +1.86% | +4.07% | |
| Form 10-Q Phathom Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.09% | -2.27% | |
| Form 8-K Phathom Pharmaceuticals, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -2.09% | -2.27% | |
| Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.09% | -2.27% | |
| Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 | Press release | GlobeNewswire | -0.39% | +2.43% | |
| Form ARS Phathom Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.18% | +1.67% | |
| Form DEF 14A Phathom Pharmaceuticals, For: May 19 | SEC filing · Form DEF | SEC EDGAR | +0.09% | +1.63% | |
| Form DEFA14A Phathom Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.18% | +1.67% | |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.10% | -0.97% | |
| Form S-8 Phathom Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +2.61% | +1.74% | |
| Form 10-K Phathom Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.51% | +4.71% | |
| Form 8-K Phathom Pharmaceuticals, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +4.71% | |
| Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Press release | GlobeNewswire | +1.51% | +4.71% | |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.06% | -0.44% | |
| Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 | Press release | GlobeNewswire | -0.25% | +6.07% | |
| Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 | Press release | GlobeNewswire | -0.75% | -6.76% | |
| Form 8-K Phathom Pharmaceuticals, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -1.99% | -3.75% | |
| Form 8-K Phathom Pharmaceuticals, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | -2.50% | |
| Form S-3ASR Phathom Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | -2.06% | -2.50% | |
| Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.06% | -2.50% | |
| Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.06% | -2.50% | |
| Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.06% | -2.50% | |
| Form 8-K Phathom Pharmaceuticals, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -0.88% | |
| Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) | Press release | GlobeNewswire | -0.51% | -0.88% | |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.18% | +1.63% | |
| Form 10-Q Phathom Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.79% | -4.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PHAT section they belong to.
Where else PHAT is measured.
PHAT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Phathom Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled PHAT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 292 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of PHAT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PHAT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.